78 Monoolein for Sale
Compare supplier listings for Monoolein (CAS 25496-72-4) — check price, grade and packaging, then open a product page or send an inquiry. View Suppliers
Glyceryl monooleate
-
Price:
Price on request
-
CAS No.:
25496-72-4
Monoolein
-
Price:
Price on request
-
CAS No.:
25496-72-4
-
Packaging:
200 & 50 kgs HDPE Barrel & Carboy
Products You May Be Interested in
Monoolein
-
Price:
Price on request
-
CAS No.:
25496-72-4
Glyceryl monooleate
-
Price:
Price on request
-
CAS No.:
25496-72-4
Monoolein
-
Price:
Price on request
-
CAS No.:
25496-72-4
Glycerol mono-oleate
-
Price:
Price on request
-
CAS No.:
25496-72-4
Glyceryl monooleate
-
Price:
Price on request
-
CAS No.:
25496-72-4
About Monoolein List
- If you want to buy Tirzepatide, then ECHEMI will offer you multi-options. Suppliers of 78 Tirzepatide registered will be verified by the accurate information. To make sure the safety of the transaction on ECHEMI, we will make sure the information is trust-worthy of each supplier. Find your Tirzepatide order with 70000+ buyers on ECHEMI.
- Tirzepatide 2023788-19-2 from ECHEMI are quality guaranteed. Our business partners are with certification, quanlification and so on. And we are familiar with the regulatory requirements from different areas of Tirzepatide. Customized services of Tirzepatide will provided to customers on ECHEMI.
- Tirzepatide in reasonable and fair market price will be provided with better options and services. Member registered on ECHEMI will enjoy services of Tirzepatide for example market price and insights and trade data. Efficient order options is the key for supply chain services we offer for you. We will help you purchase Tirzepatide and run fast your business.
Check Out More Resources
- •China’s Hybio Takes Generic Tirzepatide to FDA: Lilly’s GLP-1 Fortress Gets a Warning Shot
- •Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
- •Novo Nordisk’s Semaglutide Faces Strong Competition: Eli Lilly’s Tirzepatide Officially Launched in China
- •Eli Lilly Revenue Reaches $31.5 Billion, Up 27%! Tirzepatide and Semaglutide Exceed $20 Billion
- •Novo Nordisk's 2024 Earnings Surge by 23%! Diabetes Drug Sales Skyrocket, but Facing Competition Pressure from Tirzepatide